Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Site Map
Lilly Medical
olumiant-baricitinib-incidence-of-pneumonia-in-the-rheumatoid-arthritis-clinical-development-program
olumiant-baricitinib-changes-in-haemoglobin-in-the-rheumatoid-arthritis-clinical-development-program
zypadhera-olanzapine-pamoate-recommended-needles-for-administration-in-patients-with-low-body-weight
taltz-ixekizumab-inflammatory-bowel-disease-adverse-events-in-the-pediatric-psoriasis-clinical-trial
taltz-ixekizumab-can-it-be-used-in-patients-with-hepatic-impairment-is-a-dose-adjustment-recommended